Insider Selling: Caribou Biosciences (NASDAQ:CRBU) Insider Sells $13,598.48 in Stock

Caribou Biosciences, Inc. (NASDAQ:CRBU) insider Ruhi Ahmad Khan sold 6,938 shares of the firm’s stock in a transaction on Tuesday, February 24th. The stock was sold at an average price of $1.96, for a total value of $13,598.48. Following the transaction, the insider directly owned 104,998 shares of the company’s stock, valued at $205,796.08. The trade was a 6.20% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Caribou Biosciences Stock Up 2.1%

CRBU opened at $1.99 on Friday. The firm has a market cap of $186.01 million, a P/E ratio of -1.17 and a beta of 2.61. The business’s fifty day simple moving average is $1.63 and its 200 day simple moving average is $1.91. Caribou Biosciences, Inc. has a 52 week low of $0.66 and a 52 week high of $3.54.

Hedge Funds Weigh In On Caribou Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. grew its holdings in shares of Caribou Biosciences by 80.0% during the 4th quarter. Russell Investments Group Ltd. now owns 24,347 shares of the company’s stock worth $39,000 after purchasing an additional 10,824 shares during the period. Green Alpha Advisors LLC lifted its position in Caribou Biosciences by 3.1% during the fourth quarter. Green Alpha Advisors LLC now owns 375,139 shares of the company’s stock valued at $596,000 after buying an additional 11,440 shares in the last quarter. CWM LLC grew its stake in Caribou Biosciences by 53.5% during the second quarter. CWM LLC now owns 33,839 shares of the company’s stock worth $43,000 after buying an additional 11,798 shares during the period. R Squared Ltd purchased a new stake in Caribou Biosciences during the third quarter worth approximately $29,000. Finally, Bronte Capital Management Pty Ltd. acquired a new stake in shares of Caribou Biosciences in the fourth quarter worth $25,000. 77.51% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on CRBU shares. HC Wainwright boosted their price objective on shares of Caribou Biosciences from $3.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Caribou Biosciences in a report on Wednesday, January 21st. Citigroup upped their target price on Caribou Biosciences from $5.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 3rd. Finally, Truist Financial set a $7.00 price target on Caribou Biosciences in a report on Tuesday, November 4th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Caribou Biosciences has a consensus rating of “Hold” and a consensus price target of $8.00.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.